Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

Publisher： Karger

E-ISSN： 1423-0399|93|1|49-54

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.93, Iss.1, 2013-11, pp. : 49-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 76, Iss. 6, 2009-05 ,pp. : 442-446

Karger

Access to resources Recommend Favorite

Feasibility of Tri-Weekly Docetaxel-Based Chemotherapy for Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer

By  

Urologia Internationalis, Vol. 87, Iss. 3, 2011-08 ,pp. : 263-269

Karger

Access to resources Recommend Favorite

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3636-3643

John Wiley & Sons Inc

Access to resources Recommend Favorite

Castrate-resistant prostate cancer: the right targets and combinations

By Karakunnel Joyson   Dahut William  

Therapy, Vol. 5, Iss. 1, 2008-01 ,pp. : 57-61

Future Medicine

Access to resources Recommend Favorite

Very Fast Recovery of Acute Disseminated Intravascular Coagulation with Abiraterone Acetate in a Patient with Bone Metastases from Castrate-Resistant Prostate Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 625-627

Karger

Access to resources Recommend Favorite